Related references
Note: Only part of the references are listed.Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma
R. Donald Harvey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure
Francois Lefrere et al.
TRANSFUSION (2013)
Prospective cohort study of the circadian rhythm pattern in allogeneic sibling donors undergoing standard granulocyte colony-stimulating factor mobilization
Patricia A. Shi et al.
STEM CELL RESEARCH & THERAPY (2013)
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Dennis L. Cooper et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Diabetic Stem-Cell Mobilopathy
John F. DiPersio
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Diabetes Impairs Hematopoietic Stem Cell Mobilization by Altering Niche Function
Francesca Ferraro et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Cooperation of beta(2)- and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization
Simon Mendez-Ferrer et al.
SKELETAL BIOLOGY AND MEDICINE (2010)
Variation in cell yield and proliferative activity of positive selected human CD34+ bone marrow cells along the circadian time scale
J. Foss Abrahamsen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient
Patrick Stiff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Pharmacokinetics and Pharmacodynamics of Plerixafor in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma
Douglas A. Stewart et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
John F. DiPersio et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma
Amanda Cashen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients
Yair Gazitt et al.
STEM CELLS AND DEVELOPMENT (2007)
Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients
Giorgina Specchia et al.
ACTA HAEMATOLOGICA (2006)
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone
N Flomenberg et al.
BLOOD (2005)
A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100
NA Lack et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Share Paper
